Open Access

A biregional survey and review of first-line treatment failure and second-line pediatric antiretroviral access and use in Asia and southern Africa

  • TREAT Asia Pediatric HIV Observational Database (TApHOD)1_846 and
  • The International Epidemiologic Databases to Evaluate AIDS (IeDEA) Southern Africa Paediatric Group2_846
Journal of the International AIDS Society201114:17

https://doi.org/10.1186/1758-2652-14-17

Received: 28 March 2011

Accepted: 8 April 2011

Published: 8 April 2011

Correction

The article published in [1], contains incorrect data in Table 1 regarding the nationally recommended paediatric second-line ART regimen after NNRTI failure in India. This has been corrected. The editors and authors regret the inconvenience caused to readers by the error in the original paper.
Table 1

First- and second-line antiretroviral therapy regimens in use in TREAT Asia and IeDEA Southern Africa

Site

Country

Nationally recommended paediatric first-line ART regimen*

Nationally recommended paediatric second-line ART regimen after NNRTI

Most commonly used second-line regimen in current site cohort

TREAT Asia

    

National Center for HIV, AIDS, Dermatology, and Sexually Transmitted Infections

Cambodia

d4T or AZT+3TC+NVP or EFV

If NNRTI exposure:

d4T+3TC+LPV/r

ABC+ ddI+LPV/r

ABC+3TC+LPV/r

Beijing Ditan Hospital

China

d4T or AZT+3TC+NVP or EFV

If NNRTI exposure:

AZT+3TC+LPV/r

ABC+3TC+AZT+LPV/r

ABC+3TC+AZT+LPV/r

YRG Centre for AIDS Research and Education

India

d4T or AZT+3TC+NVP or EFV

ABC+ddI+3TC+LPV/r

TDF or ddI+3TC or FTC+LPV/r

Cipto Mangunkusumo Hospital

Indonesia

d4T or AZT+3TC+NVP or EFV

ddI+3TC+LPV/r

ddI+3TC+LPV/r

Hospital Kuala Lumpur

Malaysia

<3yr:

AZT+3TC or ddI+NVP

≥3yr:

AZT+3TC or ddI+EFV

2 new NRTI+LPV/r

d4T+3TC+LPV/r

Hospital Likas

Malaysia

<3yr:

AZT+3TC or ddI+NVP

≥3yr:

AZT+3TC or ddI+EFV

2 new NRTI+LPV/r

d4T+ddI+LPV/r

Hospital Penang

Malaysia

<3yr:

AZT+3TC or ddI+NVP

≥3yr:

AZT+3TC or ddI+EFV

2 new NRTI+LPV/r

--

Hospital Raja Perempuan Zainab

Malaysia

<3yr:

AZT+3TC or ddI+NVP

≥3yr:

AZT+3TC or ddI+EFV

2 new NRTI+LPV/r

d4T+ddI+LPV/r

Chiang Mai University Medical Centre

Thailand

d4T or AZT+3TC+NVP or EFV

ddI+ABC or 3TC+PI/r

AZT+3TC+LPV/r

Chiang Rai Regional Hospital

Thailand

d4T or AZT+3TC+NVP or EFV

ddI+ABC or 3TC+PI/r

AZT+3TC+LPV/r

HIV-NAT

Thailand

d4T or AZT+3TC+NVP or EFV

ddI+ABC or 3TC+PI/r

AZT+3TC+LPV/r

Khon Kaen University Medical Centre

Thailand

d4T or AZT+3TC+NVP or EFV

ddI+ABC or 3TC+PI/r

AZT+ddI+LPV/r

Siriraj Hospital

Thailand

d4T or AZT+3TC+NVP or EFV

ddI+ABC or 3TC+PI/r

AZT+ddI+LPV/r

Children's Hospital 1

Vietnam

d4T+3TC+NVP

ABC+ddI+LPV/r

--

Children's Hospital 2

Vietnam

d4T+3TC+NVP

ABC+ddI+LPV/r

ABC+ddI+LPV/r

National Hospital of Paediatrics

Vietnam

d4T+3TC+NVP

ABC+ddI+LPV/r

ABC+ddI+LPV/r

IeDEA Southern Africa

    

Lighthouse Clinic

Malawi

d4T+3TC+NVP

ABC+ddI+LPV/r

AZT+3TC+LPV/r

Paediatric Day Hospital, Maputo

Mozambique

d4T or AZT+3TC+NVP or EFV

If NNRTI exposure:

d4T or AZT+3TC+LPV/r

ABC+ddI+LPV/r

None

Rahima Moosa Mother and Child Hospital

South Africa

<3yr/10kg:

d4T+3TC+LPV/r

>3yr/10kg:

d4T+3TC+EFV

AZT+ddI+LPV/r

ABC+3TC+LPV/r

Gugulethu Community Health Centre

South Africa

<3yr/10kg:

d4T+3TC+LPV/r

>3yr/10kg:

d4T+3TC+EFV

AZT+ddI+LPV/r

AZT+ddI+EFV or LPV/r ABC+3TC+LPV/r

Harriet Shezi Clinic

South Africa

<3yr/10kg:

d4T+3TC+LPV/r

>3yr/10kg:

d4T+3TC+EFV

AZT+ddI+LPV/r

AZT+ddI+LPV/r

Khayelitsha Community Health Centre

South Africa

<3yr/10kg:

d4T+3TC+LPV/r

>3yr/10kg:

d4T+3TC+EFV

AZT+ddI+LPV/r

AZT+ddI+LPV/r

McCord Hospital

South Africa

<3yr/10kg:

d4T+3TC+LPV/r

>3yr/10kg:

d4T+3TC+EFV

AZT+ddI+LPV/r

AZT+ddI+LPV/r

Red Cross Children's Hospital

South Africa

<3yr/10kg:

d4T+3TC+LPV/r

>3yr/10kg:

d4T+3TC+EFV

AZT+ddI+LPV/r

AZT+ddI+EFV

Tygerberg Hospital

South Africa

<3yr/10kg:

d4T+3TC+LPV/r

>3yr/10kg:

d4T+3TC+EFV

AZT+ddI+LPV/r

AZT+ddI+LPV/r

Newlands Clinic

Zimbabwe

AZT+3TC+NVP

ddI+3TC+LPV/r

d4T+3TC+NVP

*Content reflects current recommendations at the time of the survey. WHO first-line regimen recommendations at the time of the survey included two NRTIs with one NNRTI or two NRTIs with one PI/r if the infant had previous NNRTI exposure [10,17]; second-line regimen recommendations after NNRTI failure included two NRTIs with one PI/r or unboosted nelfinavir in limited circumstances.

d4T - stavudine; AZT - zidovudine; 3TC - lamivudine; NVP - nevirapine; EFV - efavirenz; ABC - abacavir; ddI - didanosine; LPV/r - ritonavir-boosted lopinavir; TDF - tenofovir; FTC - emtricitabine; NRTI - nucleoside reverse transcriptase inhibitor; NNRTI - non-nucleoside reverse transcriptase inhibitor.

Authors’ Affiliations

(1)
TREAT Asia/amfAR - The Foundation for AIDS Research
(2)
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland and the School of Public Health and Family Medicine, University of Cape Town

References

  1. TREAT Asia Pediatric HIV Observational Database (TApHOD), and The International Epidemiologic Databases to Evaluate AIDS (IeDEA) Southern Africa Paediatric Group: A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa. J Int AIDS Soc 2011,14(1):7.View ArticleGoogle Scholar

Copyright

© TREAT Asia Pediatric HIV Observational Database (TApHOD) and The International Epidemiologic Databases to Evaluate AIDS (IeDEA) Southern Africa Paediatric Group; licensee BioMed Central Ltd. 2011

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement